Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist administered once weekly, produces significant weight loss (8.6% to 20.9%) and metabolic improvements in obese patients, outperforming placebo and demonstrating superior efficacy compared to semaglutide in head-to-head comparisons.
Tirzepatide is a once-weekly injection that helps obese patients lose significant weight (up to 20%) and improves blood sugar and heart risk factors. It works by mimicking hormones that regulate appetite and digestion. While it can cause temporary stomach issues like nausea, it is generally well-tolerated and more effective than some other existing weight-loss drugs. Medical supervision is required to manage dosing and side effects.
The results indicate that tirzepatide is a promising and safe therapy for weight loss in patients with obesity. All studies reported significant weight loss in patients treated with this therapy, ranging from 8.6% to 16.0% of baseline body weight... Tirzepatide... produced 13.1% of weight loss over 40 weeks... adults with obesity subjected to weekly therapy achieved an average weight reduction of 19.5% and 20.9% with doses of 10 mg and 15 mg of tirzepatide, respectively, compared to a weight reduction of 3.1% with placebo.
Why this rating
Based on multiple randomized controlled trials (RCTs) and systematic reviews, though the paper itself is a review of other studies.
Source
Análise da eficácia da Tirzepatida como agente terapêutico para perda de peso em pacientes com Obesidade
Francisco Kelton Araujo Lira et al. · Brazilian Journal of Development · 2023
DOI 10.34117/bjdv9n5-092
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →